Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer
This work describes a novel mechanism for CDK12, suggesting a potential vulnerability in ER+ breast cancer. These findings provide a basis for further investigation into the role of CDK12 inhibition as a therapeutic approach, particularly in advanced disease settings.
Authors
- Steffi Oesterreich (ORCID: https://orcid.org/0000-0002-2537-6923)
- Shannon Kalsi
- Petra Jagušt (ORCID: https://orcid.org/0000-0001-5291-251X)
- Daniela Ottaviani (ORCID: https://orcid.org/0000-0001-6573-162X)
- Leonie S. Young (ORCID: https://orcid.org/0000-0002-4904-0367)
- Seán Hickey (ORCID: https://orcid.org/0009-0003-2795-8681)
- Nicola Cosgrove (ORCID: https://orcid.org/0000-0002-8296-115X)
- Katherine M. Sheehan (ORCID: https://orcid.org/0000-0002-8969-3610)
- Aisling Hegarty (ORCID: https://orcid.org/0000-0002-4514-3334)
- Adrian V. Lee (ORCID: https://orcid.org/0000-0001-9917-514X)
- Stephen Shovlin
- Arfon Powell (ORCID: https://orcid.org/0000-0002-3740-8275)
- Mihaela Ola
- Yasmina Chaibi (ORCID: https://orcid.org/0000-0002-9734-172X)
- Ed Ainscow
- Sinéad Cocchiglia (ORCID: https://orcid.org/0000-0002-1596-1950)
- Damir Varešlija (ORCID: https://orcid.org/0000-0003-1000-0357)
- Alessandra Allotta (ORCID: https://orcid.org/0000-0002-7684-2031)
- Lance Hudson
- Gordon Daly
- Fergus J. Couch
- Arnold D. Hill
- Fiona T. Bane
- Ash K. Bahl (ORCID: https://orcid.org/0009-0004-4316-546X)
- Ramón Fallon
Institutions
- Mayo Clinic (US)
- Royal College of Surgeons in Ireland (IE)
- University of Pittsburgh (US)
- Beaumont Hospital (IE)
- Akebia Therapeutics (United States) (US)
- Magee-Womens Research Institute (US)
- Mayo Clinic in Arizona (US)
- Swim Ireland (IE)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1093/jnci/djaf295
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09